orantinib

an antiangiogenic agent

Also Known As:

SU6668; (Z)- 3- (2,4- dimethyl- 5- (2- oxo- 1,2- dihydro- indol- 3- ylidenemethyl)- 1H- pyrrol- 3- yl)- propionic acid; (Z)- 3- (2,4- dimethyl- 5- (2- oxo- 1,2- dihydro- indol- 3- ylidenemethyl)- 1H- pyrrol- 3- yl)propionic acid; 5- ((1,2- dihydro- 2- oxo- 3H- indol- 3- ylidene)methyl)- 2,4- dimethyl- 1H- pyrrole- 3- propanoic acid; SU 6668; SU-6668; SU006668; TSU 68; TSU-68

Pharmalogical Action Categories:

D047428 - Protein Kinase Inhibitors

Heterocyclic Compounds: 207
- Alkaloids: 5592
  - Indole Alkaloids: 206
    - Oxindoles: 124
      - orantinib: 77
- 1-Ring Heterocyclic Compounds
  - Azoles: 2199
    - Pyrroles: 381
      - orantinib: 77
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 205
      - Indole Alkaloids: 206
        Oxindoles: 124
        orantinib: 77
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 206
        Oxindoles: 124
        orantinib: 77
Organic Chemicals: 140
- Carboxylic Acids: 986
  - Acyclic Acids
    - Propionates: 1013
      - orantinib: 77
Lipids: 118169
- Fatty Acids: 28212
  - Volatile Fatty Acids: 3325
    - Propionates: 1013
      - orantinib: 77

E Nicolato Selected Research

E Nicolato Research Topics

Disease

Drug/Important Bio-Agent (IBA)